Peringatan Keamanan

No evidence of toxicity. Adverse effect of excessive clotting in certain individuals.

Coagulation factor VII human

DB13150

biotech approved investigational

Deskripsi

Coagulation factor VII is human serine protease type enzyme that is involved in the extrinsic coagulation cascade which results in blood clotting.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 5 h
Volume Distribusi 45 ml/kg
Klirens (Clearance) 7.4 ml/kgh

Absorpsi

No absorption since given IV.

Metabolisme

Degraded by catabolism

Rute Eliminasi

Catabolism

Interaksi Obat

90 Data
Aminocaproic acid The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Coagulation factor VII human.
Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation factor VII human.
Menadione Menadione may increase the thrombogenic activities of Coagulation factor VII human.
Tranexamic acid Tranexamic acid may increase the thrombogenic activities of Coagulation factor VII human.
Aprotinin Aprotinin may increase the thrombogenic activities of Coagulation factor VII human.
Hydrogen peroxide Hydrogen peroxide may increase the thrombogenic activities of Coagulation factor VII human.
Aminomethylbenzoic acid Aminomethylbenzoic acid may increase the thrombogenic activities of Coagulation factor VII human.
Camostat Camostat may increase the thrombogenic activities of Coagulation factor VII human.
Menadione bisulfite Menadione bisulfite may increase the thrombogenic activities of Coagulation factor VII human.
Monteplase The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Monteplase.
Lepirudin The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Lepirudin.
Bivalirudin The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Bivalirudin.
Alteplase The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Alteplase.
Urokinase The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Urokinase.
Reteplase The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Reteplase.
Anistreplase The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Anistreplase.
Tenecteplase The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Tenecteplase.
Abciximab The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Abciximab.
Drotrecogin alfa The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Drotrecogin alfa.
Streptokinase The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Streptokinase.
Dicoumarol The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Dicoumarol.
Argatroban The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Argatroban.
Ardeparin The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Ardeparin.
Phenindione The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Phenindione.
Fondaparinux The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Fondaparinux.
Warfarin The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Warfarin.
Pentosan polysulfate The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Pentosan polysulfate.
Phenprocoumon The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Phenprocoumon.
Dipyridamole The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Dipyridamole.
Heparin The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Heparin.
Enoxaparin The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Enoxaparin.
Epoprostenol The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Epoprostenol.
Acenocoumarol The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Acenocoumarol.
4-hydroxycoumarin The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with 4-hydroxycoumarin.
Coumarin The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Coumarin.
Ximelagatran The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Ximelagatran.
Desmoteplase The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Desmoteplase.
Defibrotide The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Defibrotide.
Ancrod The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Ancrod.
Beraprost The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Beraprost.
Prasugrel The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Prasugrel.
Rivaroxaban The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Rivaroxaban.
Sulodexide The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Sulodexide.
Idraparinux The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Idraparinux.
Cangrelor The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Cangrelor.
Astaxanthin The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Astaxanthin.
Apixaban The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Apixaban.
Otamixaban The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Otamixaban.
Amediplase The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Amediplase.
Dabigatran etexilate The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Dabigatran etexilate.
Danaparoid The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Danaparoid.
Dalteparin The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Dalteparin.
Tinzaparin The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Tinzaparin.
(R)-warfarin The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with (R)-warfarin.
Ethyl biscoumacetate The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Ethyl biscoumacetate.
Nadroparin The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Nadroparin.
Triflusal The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Triflusal.
Ticagrelor The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Ticagrelor.
Ditazole The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Ditazole.
Vorapaxar The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Vorapaxar.
Edoxaban The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Edoxaban.
Sodium citrate The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Sodium citrate.
Dextran The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Dextran.
Bemiparin The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Bemiparin.
Parnaparin The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Parnaparin.
Desirudin The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Desirudin.
Antithrombin Alfa The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Antithrombin Alfa.
Antithrombin III human The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Antithrombin III human.
Letaxaban The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Letaxaban.
Darexaban The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Darexaban.
Betrixaban The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Betrixaban.
Nafamostat The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Nafamostat.
Gabexate The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Gabexate.
Fluindione The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Fluindione.
Brinase The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Brinase.
Clorindione The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Clorindione.
Diphenadione The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Diphenadione.
Tioclomarol The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Tioclomarol.
Melagatran The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Melagatran.
Saruplase The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Saruplase.
(S)-Warfarin The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with (S)-Warfarin.
Tocopherylquinone The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Tocopherylquinone.
Dabigatran The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Dabigatran.
Semuloparin The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Semuloparin.
Troxerutin The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Troxerutin.
Edetic acid The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Edetic acid.
Reviparin The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Reviparin.
Dermatan sulfate The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Dermatan sulfate.
SR-123781A The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with SR-123781A.
Limaprost The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Limaprost.

Target Protein

Tissue factor F3
Coagulation factor X F10
Coagulation factor IX F9

Referensi & Sumber

Synthesis reference: Björkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clinical Pharmacokinetics serial on the Internet. (2001), cited March 3, 2017; 40(11): 815-832. Available from: MEDLINE. Mackman, N. (2009). The Role of Tissue Factor and Factor VIIa in Hemostasis. Anesthesia and Analgesia, 108(5), 1447–1452. http://doi.org/10.1213/ane.0b013e31819bceb1
Artikel (PubMed)
  • PMID: 11198768
    Cartmill M, Dolan G, Byrne JL, Byrne PO: Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg. 2000 Oct;14(5):458-61.
  • PMID: 26714677
    Frontera JA, Lewin JJ 3rd, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, del Zoppo GJ, Kumar MA, Peerschke EI, Stiefel MF, Teitelbaum JS, Wartenberg KE, Zerfoss CL: Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016 Feb;24(1):6-46. doi: 10.1007/s12028-015-0222-x.
  • PMID: 7354023
    Broze GJ Jr, Majerus PW: Purification and properties of human coagulation factor VII. J Biol Chem. 1980 Feb 25;255(4):1242-7.

Contoh Produk & Brand

Produk: 8 • International brands: 0
Produk
  • Balfaxar
    Powder, for solution • - • Intravenous • US • Approved
  • Beriplex P/n 1000
    Powder, for solution • - • Intravenous • Canada • Approved
  • Beriplex P/n 500
    Powder, for solution • - • Intravenous • Canada • Approved
  • Feiba Vh Immuno Anti Inhibitor
    Powder, for solution • - • Intravenous • Canada • Approved
  • Kcentra
    Injection, powder, lyophilized, for solution; Kit • - • Intravenous • US • Approved
  • Kcentra
    Injection, powder, lyophilized, for solution; Kit • - • Intravenous • US • Approved
  • Octaplex
    Kit; Powder, for solution • - • Intravenous • Canada • Approved
  • Octaplex
    Kit; Powder, for solution • - • Intravenous • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul